exarafenib   Click here for help

GtoPdb Ligand ID: 12095

Synonyms: compound 15 [Chen et al., 2024] [1] | example 14 [WO2021081375A1] | KIN-2787 | KIN2787
PDB Ligand
Compound class: Synthetic organic
Comment: We obtained the chemical structure for exarafenib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as an antineoplastic. The structure is claimed in Kinnate Biopharma's patent WO2021081375A1 [2]. This patent claims the compound as a RAF kinase inhibitor, for potential to treat cancers that are driven by RAF oncogenes. Kinnate Biopharma's pipeline includes their phase 1 pan-RAF inhibitor KIN-2787. Formal disclosure of exarafenib's chemical structure in January 2024 confirmed our name-to-structure prediction [1]. Exarafenib is a pan-RAF inhibitor that is capable of inhibiting aberrant MAPK signalling via both mono- and dimeric RAF structures.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 89.96
Molecular weight 521.26
XLogP 5.13
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC[C@H](Nc1cc(cc(n1)N1CCOCC1)c1cc(ccc1C)NC(=O)N1CC[C@H](C1)CC(F)(F)F)C
Isomeric SMILES Cc1c(cc(cc1)NC(=O)N1CC[C@H](C1)CC(F)(F)F)c1cc(nc(c1)N1CCOCC1)N[C@H](C)CO
InChI InChI=1S/C26H34F3N5O3/c1-17-3-4-21(31-25(36)34-6-5-19(15-34)14-26(27,28)29)13-22(17)20-11-23(30-18(2)16-35)32-24(12-20)33-7-9-37-10-8-33/h3-4,11-13,18-19,35H,5-10,14-16H2,1-2H3,(H,30,32)(H,31,36)/t18-,19+/m1/s1
InChI Key GZMYLSJUNSCMTD-MOPGFXCFSA-N
No information available.
Summary of Clinical Use Click here for help
Exarafenib (KIN-2787) is a clinical candidate for the treatment of selected advanced solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04913285 A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors Phase 1 Interventional Kinnate Biopharma